ClinicalTrials.gg
CompletedNCT06414031TATRAUpdated Oct 7, 2026

Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

A Phase 3 interventional study of Tranexamic Acid and Placebo in Surgical Blood Loss, Transfusion-dependent Anemia and Abdomen Disease, sponsored by Ulrich Ronellenfitsch, MD. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Ulrich Ronellenfitsch, MD · Phase 3, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.

Enrollment
2nd of 46
892 · median 98
Started
2024
with 1 other
Phase 3
9 of 46
4 open now
Registered
35th of 46
by date

Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one is the 2nd largest by enrollment, is one of 2 that started in 2024, is one of 9 in phase 3, and was the 35th registered.

Blood Loss, Surgical

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

Browse Blood Loss, Surgical studies →

Open to participants now

9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing Tranexamic Acid in Blood Loss, Surgical, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the administration of tranexamic acid can reduce the necessity of blood transfusions in adult patients undergoing major abdominal surgery. . It will also inform about safety of tranexamic acid in this setting.

The main question it aims to answer is: Does tranexamic acid lower the probability of receiving at least one blood transfusion during or after surgery?

Participants will compare tranexamic acid o a placebo (a look-alike substance that contains no drug) to see if tranexamic acid works to reduce the necessity of a blood transfusion.

03

Conditions studied

  • Surgical Blood Loss
  • Transfusion-dependent Anemia
  • Abdomen Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or above
  2. Planned elective esophagectomy, gastrectomy, colectomy, rectal resection, pancreatic resection, or hepatectomy
  3. Adequate renal function with serum creatinine \<250 µmol/L (2.82 mg/dL)
  4. Written obtained before randomization
  5. Negative pregnancy test for women of within 14 days of commencing study treatment. Females of must agree to practice highly effective measures during the study. These comprise measures with a failure rate of \<1% per year when used consistently and correctly, such as intravaginal and transdermal combined (oestrogen and progestogen containing) hormonal contraception, injectable and implantable progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion; vasectomised partner, sexual abstinence (defined as refraining from heterosexual intercourse during the entire study period).

Exclusion criteria

Exclusion Criteria:

  1. Severe anaemia, defined as a concentration \<8 g/dL (\<5 mmol/L) or anaemia with haemoglobin concentration ≥8 to \<10 g/dL (≥5,0 to \<6,2 mmol/l) and one or several of the following symptoms suggesting hypoxemia:

    • Clinical signs of tachycardia, e.g., resting heart rate >100 beats/minute, palpitation etc.
    • Clinical signs of hypotension, e.g., resting systolic blood pressure \<100 mmHg, orthostatic dysregulation etc.
    • Clinical signs of dyspnea, e.g., speech dyspnea, resting respiratory rate >20 breaths/min.
  2. Thrombocytopenia with \<60 x 109 /L
  3. Confirmed bleeding disorder with the need for specific preventive perioperative treatment (e.g., factor deficiency with the need of perioperative substitution)
  4. A priori refusal of blood transfusions
  5. Confirmed thrombophilia with a pertinent need for perioperative anticoagulation
  6. Allergy / to tranexamic acid
  7. Recent (\<30 days) thromboembolic event
  8. History of medically confirmed convulsions
  9. In female subjects: pregnancy or lactation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
892 participants (actual)

Study arms

  • Experimental
    Tranexamic acid

    Intravenous administration of tranexamic acid (1 g bolus 10 minutes prior to skin incision followed by continuous infusion 125 mg / hour until skin closure)

    Drug: Tranexamic Acid

  • Placebo comparator
    Placebo

    Intravenous administration of placebo (normal saline), 50 ml bolus 10 minutes prior to skin incision followed by continuous infusion of 6.25 ml / hour until skin closure.

    Drug: Placebo

Interventions

  • Intravenous administration

    Also known as: Tranexamsäure Carinopharm 100mg/ml

  • DrugPlacebo

    Intravenous administration

    Also known as: Isotone Kochsalz-Lösung 0,9% Infusionslösung

06

What researchers measure

Primary outcomes

  1. Transfusion necessity

    Intra- or postoperative transfusion of at least one unit of packed red blood cells

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

Secondary outcomes

  1. Transfusion amount

    Number of transfused units of packed red blood cells per patient

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

  2. Blood loss

    Estimated intraoperative blood loss

    Time frame: From skin incision to suture

  3. Postoperative complications and mortality

    Postoperative complications and mortality assessed according to the Clavien-Dindo scheme

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

  4. Length of hospital stay

    Time period from hospital admission to discharge

    Time frame: From hospital admission to discharge

  5. Operation time

    Time period from skin incision to suture

    Time frame: From skin incision to suture

  6. Anesthesia time

    Time period from anesthesia induction to end of anesthesia

    Time frame: From anesthesia induction to end of anesthesia

  7. D-dimer levels

    Serum levels of D-dimers

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

  8. Adverse events

    Any adverse event attributed to the intervention comprising anaphylaxis, thromboembolic events, acute renal failure, acute heart failure, seizures

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

07

Study locations

2 sites
  • University Hospital Carl Gustav Carus Dresden
    Dresden, Saxony 01307, Germany
  • University Hospital, Dpt. of Abdominal, Vascular and Endocrine Surgery
    Halle, 06120, Germany
08

References and documents

Publications

  • Ronellenfitsch U, Kestel A, Klose J, Rebelo A, Bucher M, Ebert D, Mikolajczyk R, Wienke A, Kegel T, Hering J, Haiduk C, Richter M, Steighardt J, Grohmann E, Otto L, Kleeff J. Tranexamic Acid for reduction of intra- and postoperative TRansfusion requirements in elective Abdominal surgery (TATRA): study protocol for an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized superiority trial with two parallel groups. Trials. 2024 Oct 19;25(1):695. doi: 10.1186/s13063-024-08541-8. PubMed 39425234 ↗

Individual participant data

Plan to share: Yes — In accordance with data protection regulations, individual de-identified individual participant data will be shared with other researchers upon reasonable and justified request. It is planned to store de-identified individual participant data on the B2SHARE repository of the EUDAT collaborative data infrastructure.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD will be made available after analysis of the primary outcome and after publication of pertaining results.

Access criteria: Individual de-identified individual participant data will be shared with other researchers upon reasonable and justified request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Oct 2026, 27 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 14, 2024
StartActual
Jun 17, 2024
Primary completionActual
Oct 1, 2026was Nov 2026
CompletionActual
Oct 1, 2026was Nov 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 7, 2026
Primary completion
Nov 30, 2026→Oct 1, 2026 (actual)
Oct 7, 2026
Study completion
Nov 30, 2026→Oct 1, 2026 (actual)
Oct 7, 2026
Enrollment
850 (estimated)→892 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Completed
    Primary completion Nov 30, 2026→Oct 1, 2026 (now actual)
    Study completion Nov 30, 2026→Oct 1, 2026 (now actual)
    Enrollment 850 (estimated)→892 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06414031
Lead sponsor
Ulrich Ronellenfitsch, MD
Collaborators
German Federal Ministry of Education and Research, Coordinating Centre for Clinical Trials Halle
Responsible party
Ulrich Ronellenfitsch, MD (Professor of Evidence-based Abdominal Surgical Oncology, Martin-Luther-Universität Halle-Wittenberg) — Sponsor-investigator
First posted
May 14, 2024
Start date
Jun 17, 2024
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Oct 7, 2026

Study contacts

Ulrich Ronellenfitsch, MD
principal investigator · Medical Faculty of the Martin Luther University Halle-Wittenberg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion